主权项 |
1. A method for treating an ocular condition in a human subject, comprising administering to an eye of the human subject a volume of an ophthalmic formulation comprising an amount of a mTOR pathway inhibitor effective for treating the ocular condition in the human subject, wherein the mTOR pathway inhibitor is selected from the group consisting of AZD8055, BEZ235, BGT226, curcumin, farnesylthioslicyclic acid, INK128, LY294002, RGDS-conjugated LY294002, MKC-1, OSI-027, P2281, palomid 529 (P529), PI-103, PP242, PP30, QLT-0447, TAE226, TOP216, torin1, wortmannin, XL-765, EXEL-2044, EXEL-3885, EXEL-4431, EXEL-7518, YM-58483, compound 23, compound 401, PF04691502, ZSTK474, AZD6482, BKM120, CAL-101, CAL-120, CAL-263, GCS-0941, GSK-1059615, LY317615, PX-866, SF2626, WX-037, XL147, A-443654, AEZS-126, AEZS-127, AR-12, AR-42, AT13148, EZN-4150, GSK60-693, GSK1720070, KRX-0401, MK2206, SR13668, VQD-002, NV-128, GDC-0941, KU-006374, WAY-600, WYE-687, WYE-354, biolimus a9, myolimus, novolimus, ABI-009, 5-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[5,6-e]pyrimidin-7-yl]-2-methoxy-N-methylbenzamide; 4-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[5,6-e]pyrimidin-7-yl]aniline; 6-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[5,6-e]pyrimidin-7-yl]-1H-indazol-3-amine; 8-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[5,6-e]pyrimidin-7-yl]-1,2,3,4-tetrahydro-1,4-benzodiazepin-5-one; 5-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[5,6-e]pyrimidin-7-yl]-2-methoxy-N-methylbenzamide; 5-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[5,6-e]pyrimidin-7-yl]pyridin-2-amine; N-[3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[5,6-e]pyrimidin-7-yl]phenyl]methanesulfonamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[5,6-e]pyrimidin-7-yl]aniline; 5-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[6,5-d]pyrimidin-7-yl]-2-ethoxybenzamide; 5-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[5,6-e]pyrimidin-7-yl]-2-(difluoromethoxy)-N-methylbenzamide; 5-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[5,6-e]pyrimidin-7-yl]-1H-indazol-3-amine; [5-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[5,6-e]pyrimidin-7-yl]-2-methoxyphenyl]methanol; N-[[4-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[5,6-e]pyrimidin-7-yl]phenyl]methyl]methanesulfonamide; 5-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[5,6-e]pyrimidin-7-yl]-1,3-dihydroindol-2-one; 6-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[5,6-e]pyrimidin-7-yl]-1,3-dihydroindol-2-one; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; 5-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[5,6-e]pyrimidin-7-yl]-2-(difluoromethoxy)benzamide; 6-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[5,6-e]pyrimidin-7-yl]-2,3-dihydroisoindol-1-one; [5-[2-(2,6-dimethylmorpholin-4-yl)-4-morpholin-4-ylpyrido[6,5-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol; and [2-methoxy-5-[2-(3-methylmorpholin-4-yl)-4-morpholin-4-ylpyrido [6,5-d]pyrimidin-7-yl]phenyl]methanol, and pharmaceutically acceptable salts and esters thereof. |